Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, and Hidradenitis Suppurativa and Treatments.
Non‐invasive characterization of melanoma depth at single‐cell resolution
Addiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact
The loss of keratin 77 in murine skin is functionally compensated by keratin 1
The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors
S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022
S2k‐Leitlinie – Merkelzellkarzinom – Update 2022
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
Real‐world outcomes using <scp>PD</scp>‐1 antibodies and <scp>BRAF</scp> + <scp>MEK</scp> inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders (<scp>NERD<sub>ND</sub></scp>): Time to Move Beyond the Skin
Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Exceptional response to anti-PD-1 treatment in a patient with metastatic cutaneous hidradenocarcinoma
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma
The Risk of Melanoma in Airline Pilots and Cabin Crew
DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
Metformin and trametinib have synergistic effects on cell viability and tumor growth in<i>NRAS</i>mutant cancer
<i>Mycoplasma pneumoniae</i>‐associated mucositis – case report and systematic review of literature
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo